Drug Profile

Omilancor - Landos Biopharma

Alternative Names: BT 11

Latest Information Update: 21 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Landos Biopharma
Developer Landos Biopharma; NImmune Biopharma
Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
Mechanism of Action Inflammation mediator inhibitors; LANCL2 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Ulcerative colitis
Phase II Crohn's disease
Preclinical Atopic dermatitis; Eosinophilic oesophagitis; Psoriasis

Most Recent Events

10 Apr 2025 Phase-III clinical trials in Ulcerative colitis (PO) prior to April 2025
25 Oct 2024 NImmune Biopharma acquires development and commercialization rights to omilancor in Asian markets
23 May 2024 Landos Biopharma has been acquired by AbbVie

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com